2-氮杂双环(3.2.1)辛-6-烯 | 71017-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 中文名称: 2-氮杂双环(3.2.1)辛-6-烯
• 英文名称: 2-Azabicyclo[3.2.1]oct-6-ene
• 英文别名: 3-azabicyclo[3.2.1]oct-6-ene
• CAS: 71017-41-9
• 化学式: C₇H₁₁N
• mdl: MFCD09035254
• 分子量: 109.17
• InChiKey: UPCJVZGGKGONIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

文献信息

• Tyrosine Kinase Inhibitor And Uses Thereof
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20170112833A1

  公开（公告）日：2017-04-27

  Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

  公开了一种公式(I)的化合物或其药物可接受的盐、酯或溶剂，或它们的立体异构体，可用作酪氨酸激酶抑制剂。还公开了制备该化合物的方法、包含该化合物的药物组合物和套件，以及该化合物的用途。该化合物可用作酪氨酸激酶抑制剂，或可用于减少或抑制细胞中EGFR或其突变体的活性，例如包含T790M突变的EGFR突变体，或用于治疗和/或预防与EGFR过度活动相关的疾病，如癌症。
• KINASE INHIBITOR AND USE THEREOF
  申请人：Sihuan Pharmaceutical Holdings Group Ltd.

  公开号：US20180000819A1

  公开（公告）日：2018-01-04

  The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
• ß-LACTAMASE INHIBITORS AND USES THEREOF
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20180148448A1

  公开（公告）日：2018-05-31

  The present invention relates to a compound of Formula (I)-(IV) useful as β-lactamase inhibitor, a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, wherein R 1 , R 2 , M and ring A have definitions as those in the specification. The present invention further relates to methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and uses of these compounds. For example, the compounds of the present invention can be used as β-lactamase inhibitors, for treatment and/or prophylaxis of diseases caused by bacterial infections, solving drug-resistance problems caused by β-lactamases, especially bacterial drug-resistant diseases caused by type B metallo-β-lactamases.
• US9796701B2
  申请人：——

  公开号：US9796701B2

  公开（公告）日：2017-10-24
• US9949976B2
  申请人：——

  公开号：US9949976B2

  公开（公告）日：2018-04-24